Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | PLEC | Q15149 | 1/20 | 0.47 |
| ▸ | TPMT | P51580 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684356 | 0.85 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3940128 | 0.85 | KDM4E (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1759318 | 0.84 | TTR (0.56) | CA12CA1CA2CA7CA9 | |
| Hydrochloric Acid SCHEMBL4299803 | 0.84 | MAPT (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1759305 | 0.84 | TTR (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1509519 | 0.84 | KDM4E (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6051288 | 0.81 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2191755 | 0.81 | ALDH1A1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15016383 | 0.80 | CA12 (0.37) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15016382 | 0.80 | CDC25B (0.61) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1576093-A4 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | claimed |
| EP-1753861-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | Dynamis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1576093-A2 | 3-DEOXYGLUCOSONE AND SKIN | Dynamis Therapeutics, Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | claimed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | claimed |
| WO-2003089601-A2 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20210179852-A1 | Products by Upcycling Landfill Waste Streams | NYSTROM KENNETH A (US) | 2021-06-17 | — | — | US | disclosed |
| US-11034837-B2 | Products by upcycling landfill waste streams | NYSTROM KENNETH (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200362172-A1 | Products by Upcycling Landfill Waste Streams | NYSTROM KENNETH (US) | 2020-11-19 | — | — | US | disclosed |
| US-10703909-B1 | Products by upcycling landfill waste streams | NYSTROM KENNETH (US) | 2020-07-07 | — | — | US | disclosed |
| CN-105566997-A | Waste paper deinking agent and preparation method and application thereof | XUZHOU INST TECHNOLOGY | 2016-05-11 | — | — | CN | disclosed |
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| EP-1175155-A1 | METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF | FOX CHASE CANCER CENTER (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000062626-A1 | METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF | FOX CHASE CANCER CENTER (US) | 2000-10-26 | — | — | WO | disclosed |
| US-5514676-A | TO INHIBIT THE FORMATION OF ADVANCED GLYCOSLYATION PRODUCTS BY THE NONENZYMATIC CROSSLINKING OF PROTEINS WITH REDUCING SUGARS, USED IN FOOD PRESERVATION AND TO PREVENT PROTEIN AGING IN COLLAGEN OR LENSES IN THE EYE PRESERVATION | THE ROCKEFELLER UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| US-4338436-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4338439-A | BACTERICIDAL ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4319028-A | 7-(2-(Substituted benzoyl)amino)acetamido)cephalosporins | ELI LILLY AND COMPANY (US) | 1982-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | FN3K, PDXK, COLGALT1 | CA12 2753/4885CA1 1894/4885CA2 1243/4885 |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DPM1, G6PD, UGGT1 | CA12 2292/4885CA1 4084/4885CA2 1727/4885 |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | AGER, GLA, GALE | CA12 4810/4885CA1 4767/4885CA2 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.